INTRODUCTION
The advent of next generation sequencing (NGS) technology facilitates the discovery of new disease genes and is expected to transform and complement routine clinical diagnosis. This is particularly true for conditions characterised by extensive genetic heterogeneity that hampers the prioritisation of obvious candidate genes and the identification of causative mutations.
Human mitochondrial respiratory chain complex I deficiency (MIM 252010) is the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterised by faulty oxidative phosphorylation (OXPHOS), which collectively affects 1 in 5e10 000 live births. 1 Human complex I is a giant multiheteromeric structure of 45 subunits. Among these are eight Fe-S clusters and an FMN moiety, which transfer electrons from NADH to ubiquinone, using the free energy of this process to pump protons across the inner mitochondrial membrane. Seven subunits of complex I are encoded by mtDNA genes, the remaining ones by nuclear genes. Several additional gene products have been shown to contribute to its formation and activity, and further ones are hypothesised. 2 This structural and functional complexity can explain, at least in part, the extraordinary heterogeneity of complex I defects that may range from mild to severe. Complex I deficiency is known to be associated with a broad spectrum of clinical presentations, affecting single or multiple organs at any time in life. 3 Obvious genotype-phenotype correlations are missing, making inference from the biochemical or clinical presentation on the gene involved difficult or impossible. 4 Complex I deficiency is caused by a large set of disease genes, most of which are still unknown. In fact, mutations associated with complex I deficiency have been reported in 21 complex I subunits encoded by the seven mtDNA genes, and by 17 nuclear genes and in 10 accessory factors essential for complex I assembly and stability. However, these genes account for only half of the biochemically defined cases of complex I deficiency. 5 6 Taken together, these considerations make complex I deficiency a paradigmatic disorder to validate NGS protocols for diagnostic purposes.
A major hurdle for NGS to become the standard approach in routine molecular screening is the difficulty to distinguish between causal mutations and thousands of DNA sequence variants present in each individual. In this context, a distinct advantage of the biochemically well defined OXPHOS disorders is the possibility to validate the pathogenicity of a given variant by integrating in silico analysis with functional complementation in mutant cells (figure 1).
PATIENTS, MATERIALS AND METHODS Patients
Informed written consent was obtained from all participants or their guardians, and the ethics committee of the Technical University of Munich approved the study. We evaluated 10 index patients with isolated complex I deficiency. This diagnosis was based on established diagnostic criteria 7 and disease manifestation was before the age of 3 years. Accordingly, seven patients (33027, 37796, 44409, 46072, 50845, 59029, 61606) had residual complex I activities of <25% of the mean of $10 healthy controls. Another three patients (33281, 33284, 33463) had residual complex I activities between 26% and 40% in muscle and fibroblasts. Complex II, III, and IV deficiencies were biochemically excluded in all patients and none of the patients had a molecular diagnosis before. Rare mtDNA variants had been excluded by Sanger sequencing of the entire mtDNA. The clinical presentation and biochemical findings of all patients and affected siblings are summarised in table 1. A detailed case report of patient 50845 with causative mutations identified in NDUFB3 is provided in the supplementary data.
Exome sequencing and variant filtering
Within the framework of the German network for rare diseases 'mitoNET' and the European E-Rare program 'GENOMIT' we established an exome sequencing and variant filtering pipeline for the molecular diagnosis of mitochondrial disorders. The exome of individual 33284 was sequenced as 54 bp paired-end runs using two lanes of a flowcell on a Genome Analyser IIx system (Illumina, San Diego, CA, USA) after in-solution enrichment of exonic sequences using the SureSelect Human All Exon 38 Mb kit (Agilent, Santa Clara, CA, USA). All other samples were processed with the SureSelect Human All Exon 50 Mb kit (Agilent) and subsequently sequenced as 76 bp pairedend runs to an average 120 3 coverage corresponding to 9e12 Gb of sequence data. Read alignment was performed with BWA (version 0.5.8 or 0.5.9) to the human genome assembly hg19. Single nucleotide variants and small insertions and deletions were detected with SAMtools (V.0.1.7). Since mitochondrial disorders are rare conditions, we excluded variants present with a frequency >0.4% in 879 control exomes. Assuming an autosomal recessive mode of inheritance, homozygous or compound heterozygous variants were searched for (table 2) , yielding a median of 28 mutated genes per individual.
We then applied three sequential filters to identify the causal mutations: (1) a first filter for disease variants known to be associated with respiratory chain defects according to the Human Gene Mutation Database; (2) a second filter based on the identification of novel homozygous or compound heterozygous variants affecting genes encoding complex I subunits or known complex I assembly factors; and (3) a third filter for genes encoding known and predicted mitochondrial proteins listed in MitoP2. 8 
Rescue experiments and investigation of complex I assembly
In order to prove the pathogenicity of newly identified missense alleles, we tested the biochemical rescue of complex I defective skin fibroblast cell lines from three index cases after lentiviral mediated expression of wild type (wt) cDNAs using the p.Lenti6.3/V5-TOPO vector system (Invitrogen). 9 Complex I activity was measured as rotenone-sensitive oxygen consumption rate using the Seahorse system (Bioscience, North Billerica, MA, USA). 10 In the same samples, we also analysed the amount of fully assembled complex I by immuno-detection on electroblotted blue-native polyacrylamide gels using an NDUFA9 antibody as described by Nijtmans et al.
11
In patient 50845 carrying the NDUFB3 mutations, we additionally performed electrophoresis and in-gel quantification of fluorescent labelled proteins. Standard protocols for solubilisation and isolation of mitochondrial complexes 12 13 were modified to improve quantification of mitochondrial complexes from human fibroblasts.
14 Briefly, native proteins and protein complexes in homogenates from 10 mg fibroblasts (wet weight) were labelled with NHS-fluorescein (Thermo). Sediments containing mitochondrial membranes were resuspended in a buffer containing 50 mM NaCl, 50 mM imidazole, 2 mM aminohexanoic acid, and 1 mM EDTA, pH 7 and solubilised with 5 ml digitonin (20%). Following 1-D BNE (blue native electrophoresis) and 2D SDS-PAGE, the 2D gels were scanned using the blue laser (488 nm) of a Typhoon 9400 scanner (GE Healthcare) to detect fluorescein labelled proteins in mitochondrial complexes. 2D gels were further stained with silver. 15 We used the DIA module (differential in-gel analysis) of the DeCyder 2D 7.0 software (GE Healthcare) for densitometric quantification of the fluorescence intensities in 2D gels. A few clearly visible signals of subunits from ATP synthase, complexes III and IV, the supercomplexes containing complex I, III, IV, and the porin complexes 16 were selected for quantification (circled).
RESULTS

Exome analysis
By combining unbiased exome analysis, sequential filtering, and functional investigation, we report here the identification of disease mutations in five genes in seven out of 10 index cases with isolated complex I deficiency. The first filter for known Figure 1 Schematic overview of the exome study in complex I deficiency. CI, complex I; NSV, non-synonymous variants. Mito-genes refers to genes coding for known and predicted (MitoP2 SVM score $1.0) mitochondrial proteins. Numbers in parentheses indicate estimated numbers for each category.
complex I deficiency disease alleles identified homozygous mutations in two individuals, 33463 and 59029. We found previously reported missense mutations in NDUFS3 17 (MIM 603864) and ACAD9 14 (MIM 611126), coding for a structural complex I subunit and a complex I assembly factor, respectively (table 3) .
The second filter prioritised novel homozygous or compound heterozygous variants affecting genes encoding complex I subunits or known complex I assembly factors. Novel variants in such genes were identified in exomes from individuals 33284 (c.229C>T, p.Arg77Trp; c.476C>A, p.Ala159Asp in NDUFS8 (MIM 602141)), and 50845 (c.64T>C, p.Trp22Arg; c.208G>T, p.Gly70X in NDUFB3 (MIM 603839)) (table 3). Mutations in both genes have been previously shown to cause complex I deficiency. 19e21 In individual 33027 we identified variants in two genes encoding complex I subunits, NDUFS7 (c.124C>T, p.Pro42Ser; c.514C>A, p.Arg172Ser (MIM 161825)) and NDUFS8 (homozygous c.187G>C/ p.Glu63Gln). Since the equally affected sister (44559) only carried the homozygous NDUFS8 mutation, we concluded that the NDUFS7 variants were not responsible for complex I deficiency. DNA of available relatives was then tested. Concordant with a postulated pathogenic role of the NDUFS8 and NDUFB3 variants, affected individuals were homozygous (MITO021) or compound heterozygous mutants (MITO004, MITO005) (table 3), while the parents were heterozygous carriers. In the remaining samples we applied a third filter for genes encoding mitochondrial proteins listed in MitoP2 (n¼1239). 8 This filter revealed that individual 44409 was compound heterozygous for a maternal mutation c.626C>T, p.Ser209Leu and a paternal mutation c.994C>T, p.Arg332X in MTFMT (MIM 611766), the gene encoding mitochondrial methionyltRNA-formyltransferase. MTFMT has so far not been associated with isolated complex I deficiency. However, the c.626C>T mutation was recently reported in a family with Leigh syndrome, impaired mitochondrial translation, and combined OXPHOS defects. 18 The c.626C>T, p.Ser209Leu mutation was also identified in the homozygous state in patient 52075, with both reportedly non-consanguineous parents being heterozygous carriers. In addition to the predicted p.Ser209Leu change, c.626C>T has been demonstrated to cause skipping of exon 4 resulting in a frameshift and premature stop codon, p.Arg181SerfsX5. 18 The second mutation found in individual 44409, c.994C>T, p.Arg332X, determines the synthesis of a truncated variant missing the highly conserved C-terminal portion of the protein. Thus, both mutations are shown or predicted to severely impair the function of MTFMT, supporting their pathogenic impact. In metazoan mitochondria, tRNAMET plays a role in both translationinitiation as well as translation elongation. MTFMT formylates Met-tRNAMet to form fMettRNAMet. Formylated methionine-tRNA has high affinity to, and is preferentially recruited by, mitochondrial translation initiation factor (IF2mt) to theribosomal P site for translation initiation. 22 
Confirmation of the pathogenicity of NDUFS8 and NDUFB3 mutations
The newly identified disease segregating missense mutations in NDUFS8 and NDUFB3 affected amino acid residues conserved in >85% of at least 39 vertebrates. Nevertheless, their pathogenic role remained to be proven. To this aim, complementation experiments were performed followed by functional and protein level investigations. Expression of NDUFS8 wt cDNA in fibroblasts of individuals 33284 and 33027, and NDUFB3 wt in cells of patient 50845, led to a significant increase of complex I activity (figure 2). In the same samples, we also analysed the amount of fully assembled complex I by blue-native PAGE electrophoresis. The complex I content was consistently low in naïve cells, but increased significantly after expression of the corresponding wild type cDNA (figure 2).
Since expression of the NDUFB3 wt cDNA re-established complex I dependent respiration to low normal levels, we further tested the functional consequence of the identified variants in NDUFB3. The low complex I activity found in naïve cells of patient 50845 (17% of controls) remained unchanged after expression of NDUFB3 cDNA carrying either the p.Trp22Arg or the p.Gly70X mutations ( figure 3 ). In parallel we Figure 2 Introduction of NDUFS8 and NDUFB3 cDNA rescues both amount and activity of complex I in subject fibroblasts. The mutations in NDUFS8 and NDUFB3 result in decreased activity and amount of complex I. (A) 30 mg digitonin-solubilised protein from control and patients 33027, 33284, 50845 fibroblasts were separated on a 4e16% acrylamide blue-native PAGE (Novex System, Invitrogen), transferred on PVDF membrane and immuno-decorated with antibodies specific for subunits NDUFA9 of complex I and core II of complex III (1:1000; MitoSciences, Eugene, Oregon, USA). The analysis shows reduced amounts of subunit NDUFA9 assembled in supercomplex 0 and 1 (S0, S1) in patient cell lines indicating a decreased amount of whole complex I. (B) Control and patient fibroblasts were seeded at 20 000 cells/well in 80 ml DMEM, and incubated at 378C, 5% CO 2 for 24 h. Oxygen consumption rates (OCR) were measured using the XF96 extracellular flux analyser (Seahorse bioscience). The OCR was determined with no additions, and after addition of oligomycin (1 mM), carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP, 0,4 mM), and rotenone (5 mM). Complex I activity was calculated as rotenone-sensitive OCR. Both amount and activity of complex I are rescued upon lentiviralmediated stable expression of NDUFS8 wt and NDUFB3 wt cDNA. Data shown are mean of >10 biological replicates 6 SD. ***p<0.001. also showed that the NDUFB3 protein was absent in naïve cells of patient 50845, but present in an amount comparable to controls after transduction with the NDUFB3 wt cDNA. The same effect was also observed for the NDUFB8 and NDUFS3 subunits, indicating a general assembly/stability defect of complex I. The impaired complex I assembly or stability due to NDUFB3 mutations was further confirmed by two-dimensional blue-native/SDS-PAGE separation and quantification of fluorescein-labelled mitochondrial complexes (figure 4). Comparing patient and control fibroblast, the signal intensity of complex III was of the same level. Complex IV and V of patient fibroblasts were reduced to 48% and 76%, respectively. The supercomplexes were not detectable in the patient. After the transduction of the patient cell line with the NDUFB3 wt , the amounts of mitochondrial supercomplexes in patient fibroblasts increased up to 43% of the control. The amounts of complexes III, IV, and V did not change significantly.
Taken together, these results demonstrate the causal role of the mutations identified in NDUFS8 and NDUFB3, thereby establishing NDUFB3 as a gene responsible for human complex I deficiency.
DISCUSSION
In this study, increasingly wider variant filters were applied on exome sequencing datasets, in combination with functional complementation, to identify causative mutations in single individuals with complex I deficiency. Filtering of rare variants was facilitated by the availability of a large set of control exomes (n¼879), and pathogenic mutations were identified using mutation databases and in silico selection of genes encoding known or potential mitochondrial proteins. Importantly, when the list of genes was further processed against public databasesdfor example, exclusion of variants present in dbSNP with an average heterozygosity of more than 0.02dthe number of candidate genes was reduced by just one or two entries. The only exception was a sub-Saharian African individual (33027), whose gene variation dataset matched poorly with our set that was largely composed of Europeans.
Our stepwise filtering approach successfully identified variants in NDUFB3. Complementation experiments established the pathogenicity of the mutations. Two previous large candidategene based screening studies failed to identify rare DNA variants in the NDUFB3 gene among 103 5 and 152 6 patients with complex I deficiency. NDUFB3 variants were found only recently in a screen of 42 patients 19 with infantile onset mitochondrial disorders, suggesting that mutations in NDUFB3 are rare. 
